| abstract |
The invention relates to P2 agonists and antagonists or a compound which will stimulate or inhibit endogenous adenosine triphosphate (ATP) production, and more particularly to novel medical uses for same. More particularly still it relates to treating skin conditions characterised by hyperproliferation of keratinocytes, including for example, keloid formation, dermatitis and psoriasis or enhancing wound healing. The invention provides the use of an agonist or antagonist of a type P2-receptor or a compound which will stimulate or inhibit adenosine triphosphate (ATP) production for the manufacture of a medicament for treating wounds or skin conditions characterised by hyperproliferation of keratinocytes or acanthosis. It also provides a pharmaceutical composition comprising a growth factor, a pharmaceutically acceptable carrier and either an agonist of a P2Y receptor or a compound which will stimulate adenosine triphosphate (ATP) production. |